Condition: Osteogenesis Imperfecta (OI) · Sponsor: Angitia Biopharmaceuticals Guangzhou Limited
This study is to evaluate the safety and efficacy of AGA2115 at three different dose regimens in Chinese adults and adolescents with Type I, III, or IV Osteogenesis imperfecta (OI).
This description comes directly from the study's public registry record.
Yolanda Liu · +86 13911537795 · yolanda.liu@angitiabio.com
Always discuss trial participation with your own doctor first.
| Chinese Academy of Medical Sciences, Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The University of Hong Kong-Shenzhen Hospital | Shenzhen, Guangdong, China | Recruiting |
| Children's Hospital of Soochow University | Suzhou, Jiangsu, China | Not Yet Recruiting |
| Shanghai Sixth People's Hospital | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07557446